argenx's $2.2B Forte Acquisition: A Bold Play for Immunology's Future

AMSTERDAM, Netherlands & DALLAS, Texas – July 27, 2026 – In a decisive move that underscores its ambition to lead the global immunology market, argenx today announced a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion. The all-cash deal brings Forte’s first-in-class anti-CD122 antibody, FB102, into argenx’s burgeoning pipeline, a strategic maneuver aimed at redefining treatment standards for a host of autoimmune diseases that have long awaited innovation.

The acquisition, valued at $77 per share, represents a significant 86% premium over Forte's volume-weighted average stock price since its promising vitiligo data was released earlier this month. For argenx, this is more than just a transaction; it's a calculated acceleration of its "Vision 2030" strategy, a long-term plan to become the preeminent immunology innovator. By securing a clinically validated asset with broad potential, argenx is not only diversifying its portfolio beyond its current blockbuster, Vyvgart, but is also making a powerful statement about its confidence in the future of targeted immune modulation.

A Strategic Play for Immunology Dominance

The acquisition of Forte Biosciences is a cornerstone of argenx’s long-range strategy to solidify its leadership in the complex and competitive field of immunology. The company’s stated "Vision 2030" includes ambitious goals to treat 50,000 patients and advance five pipeline candidates into late-stage development. The addition of FB102, described as a potential "pipeline-in-a-product," directly serves this objective.

"Our Vision 2030 strategy is well-defined and on track, and our discovery, development and commercialization engines are delivering real value for patients," said Karen Massey, Chief Executive Officer of argenx, in a statement. "The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future. The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need."

Financed entirely from cash on hand, the deal avoids financing contingencies and signals argenx's robust financial health and conviction in the asset. The substantial premium paid reflects the high value placed on FB102 following recent clinical success. This move also provides a strategic diversification away from argenx's reliance on efgartigimod (Vyvgart), its highly successful FcRn blocker. While Vyvgart has transformed care in diseases like myasthenia gravis, the acquisition of a T-cell and NK-cell modulating agent like FB102 broadens the company's scientific toolkit, allowing it to tackle autoimmune diseases driven by different pathological pathways.

The Science and Promise of FB102

At the heart of this multi-billion-dollar deal is FB102, a monoclonal antibody with a novel mechanism of action. It targets CD122, a receptor component crucial for the signaling of two powerful cytokines, Interleukin-2 (IL-2) and Interleukin-15 (IL-15). These cytokines are key drivers of the proliferation and activity of pathogenic T-cells and Natural Killer (NK) cells, which are implicated in a wide range of autoimmune conditions. By blocking this pathway, FB102 aims to quell the specific immune cells that attack the body’s own tissues, without the broader immunosuppression associated with some older therapies.

This targeted approach has already shown significant promise in clinical trials. Forte recently reported positive Phase 1b data in vitiligo, a condition causing skin to lose its pigment. The study showed a statistically significant 29.6% mean improvement in facial repigmentation at 24 weeks. The results were particularly robust in patients with extensive disease, offering hope for a population with limited systemic treatment options.

Furthermore, FB102 has also demonstrated a positive clinical profile in celiac disease, an autoimmune disorder triggered by gluten. Following favorable Phase 1b data reported last year, the therapy received Fast Track Designation from the FDA for this indication, and Phase 2 results are eagerly anticipated in the second half of this year. This dual success was a key factor in argenx’s decision, validating the drug's potential across different diseases.

"We are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody," stated Paul A. Wagner, CEO of Forte Biosciences. He emphasized that argenx’s global reach and development expertise could accelerate the drug's journey to patients with vitiligo, celiac disease, alopecia areata, and other conditions.

Navigating a Crowded and Evolving Market

While FB102's mechanism is novel, it enters a dynamic and increasingly competitive therapeutic landscape, particularly in vitiligo. Once considered an underserved market, vitiligo now has an FDA-approved topical therapy, Incyte’s JAK inhibitor Opzelura, and a pipeline of oral JAK inhibitors from major players like AbbVie, Pfizer, and Incyte poised to enter the market. These systemic treatments are expected to become the new standard of care for patients with more widespread disease.

However, FB102's differentiated mechanism, which offers a dual blockade of IL-2 and IL-15, could provide a distinct advantage in terms of both efficacy and safety compared to the JAK inhibitor class. It addresses a significant unmet need for effective and safe systemic options for patients with extensive vitiligo, who often have limited access to or success with current phototherapy approaches.

In celiac disease, the landscape is less crowded, and the unmet need is arguably greater. The Fast Track Designation from the FDA highlights the demand for therapies beyond a strict gluten-free diet, which is the only current management strategy but is often insufficient and difficult to maintain. If successful, FB102 could become a transformative, first-in-class treatment for millions suffering from the condition.

The M&A Playbook: From Strategic Investment to Full Acquisition

The journey from a strategic partnership to a full-blown acquisition is a well-trodden path in the biotech industry, and the argenx-Forte deal is a textbook example. argenx was not a newcomer to Forte's story; it had previously participated as a strategic investor in Forte’s $150 million public offering in April 2026. This initial investment gave argenx a ringside seat to observe FB102's development, effectively de-risking the eventual multi-billion-dollar commitment.

The tipping point was the release of positive Phase 1b vitiligo data on July 9, 2026. This clinical validation sent Forte's stock soaring and acted as the catalyst for argenx to move decisively. The acquisition agreement, announced just weeks later, demonstrates a disciplined yet aggressive strategy to acquire promising, de-risked assets at a key value inflection point.

This approach allows a larger, well-capitalized company like argenx to leverage its extensive development and commercial infrastructure to maximize the potential of an asset developed by a smaller, more focused clinical-stage firm. Subject to customary closing conditions and regulatory approvals, the transaction is expected to be completed in the third quarter of 2026, officially beginning the next chapter for FB102 within the argenx portfolio.